European Restless Legs Syndrome Study Group

Annual Meeting, 9th – 10th December 2011

"Pavillon", Klinikum Rechts der Isar, Munich, Germany



Agenda

Friday, 9th December 2011 08:30 - 18:00

08:30 - 08:40Welcome and introduction

Birgit Högl (EURLSSG President), Innsbruck, Austria

Epidemiological and experimental data

(** spotlight presentations 5-minutes and 5-minutes discussion)		
	<u>Chairpersons:</u> Marco Zucconi, Milan, Italy Karin Stiasny-Kolster, Marburg, Germany	
08:40 – 09:15	Results from prospective cohort studies on RLS, with a focus on - RLS and mortality - Incidence and risk factors of RLS - Change in RLS symptoms and/or severity over time Klaus Berger, Münster, Germany	
09:15 – 09:25 **	RLS in a Georgian individuals with and without epilepsy – A questionnaire study Lia Maisuradze and Sofia Kasradze, Tbilisi, Georgia	
09:25 – 09:35 **	Restless legs syndrome and epilepsy Samson Khachatryan, Yerevan, Armenia	
09:35 – 09:45 **	RLS severity symptoms in relation to environmental and habitual conditions - the Mediterranean example. Acronym: HappyFeet Georgios Hadjigeorgiou, Larissa, Greece	
09:45 – 09:55 **	The A11 diencephalospinal pathway in non-human primates is not dopaminergic Imad Ghorayeb, Bordeaux, France	
09:55 – 10:05 **	Skeletal muscle morphology in patients with RLS Britta Wåhlin-Larsson, Örebro, Sweden	
10:05 – 10:15 **	Effects of transcutaneous spinal direct current stimulation in patients with idiopathic RLS Cornelius Bachmann, Göttingen, Germany	
10:15 – 10:45	Coffee break and discussion	

Clinical Findings I	<u>Chairpersons:</u> Magdolna Hornyak, Freiburg, Germany Georgios Hadjigeorgiou, Larissa, Greece		
10:45 – 11.00	Validation of a new interview method for the diagnosis of RLS augmentation (RLS-AUDI) Heike Benes, Schwerin, Germany		
11:00 – 11:15	Validation study of a patient-reported IRLS Ralf Kohnen, Nuremberg, Germany		
11:15 – 11:30	Experience with the Johns Hopkins RLS Diagnostic Interview Thomas Mitterling, Innsbruck, Austria		
11.30 – 11.40 **	Occurrence of periodic limb movements in primary insomnia Michaela Sebert, Berlin, Germany		
11.40 – 11:50 **	Periodic limb movements in sleep as a potential cardiovascular risk factor in hemodialysis patients: association to cardiac structure and function Christoforos Giannaki, Larissa, Greece		
11.50 – 12:00 **	Subjective and objective measures of excessive daytime sleepiness in RLS Hildegard Hidalgo, Zürich, Switzerland		
12:00 – 12:30	Discussion		
12:30 – 13:30	Lunch		

Clinical Findings II

(** spotlight presentations 5-minutes and 5-minutes discussion)

	Chairpersons:	Olli Polo, Turku, Finland Rosalia Silvestri, Messina, Italy
13:30 – 13:40 **	_	ent Strokes in Magnetic Resonance Imaging of Patients with indrome and Controls ina, Italy
13:40 – 13:50 **	Iron and glutamat Richard Allen, Balt	
13.50 – 14:00	9 5	ndrome (RLS) in children: presenting symptoms le, The Netherlands
14:00 – 14:30	Discussion	

<u>Treatment Options:</u>
(** spotlight presentations 5-minutes and 5-minutes discussion)

	<u>Chairpersons:</u> Diego Garcia Borreguero, Madrid, Spain Claudia Trenkwalder, Kassel, Germany	
14.30 – 14:40 **	Change of psychosocial impairment during treatment of RLS: what car learn from randomized controlled trials? Hanna Scholz, Freiburg, Germany	ı we
14:40 – 14:50 **	Time course of response to intravenous iron in RLS Magdolna Hornyak, Freiburg, Germany	

14:50 – 15:00 ** 15:00 – 15:10 **	Peripheral nerve compressions in the lower extremities aggravating RLS Severity: a new therapeutical option for selected patients Martin Raghunath, Munich/Frankfurt, Germany Assessing the efficacy and safety of botulinum toxin type A in patients
13.00 – 13.10	with RLS (unpublished data) Imad Ghorayeb, Bordeaux, France
15:10 – 15.20 **	Overview on non-pharmacological interventions in RLS Giorgos Sakkas, Larissa, Greece
15:20 – 15:30 **	Current Status of RLS in Finland Markku Partinen, Espoo, Finland
15:30 – 16:00	Coffee break

State-of-the-art and other news

	Chairpersons:	<u>J</u> uliane Winkelmann, Munich, Germany Birgit Högl, Innsbruck, Austria
16:00 – 16:20	•	e: current plans IRLSSG meeting September 2011 in Quebec eguero, Madrid, Spain
16:20 – 16:30	Update on genetic Juliane Winkelman	es n, Munich, Germany
16:30 – 16.40:	A unifying model Olli Polo, Tampere	of RLS: 2011 update , Finland
16.40 – 16.50	Development of the Lilo Habersack, Mu	

EURLSSG e.V. Business Meeting: (EURLSSG members only)

17.00 – 18:00 General Meeting of the EURLSSG

19:00 Dinner at the restaurant "Ritzi", Maria-Theresia-Strasse 2a

EURLSSG-Meeting and Workshop are sponsored by:

F. Hoffmann-La Roche Ltd., Pfizer Inc., UCB Pharma S.A., Vifor Pharma Deutschland GmbH, XenoPort Inc.

Agenda Workshop:

Saturday, 10th December 2011, 09:00 – 13:15

OBJECTIVE VS SUBJECTIVE MEASURES FOR DIAGNOSIS AND TREATMENT OF RLS

Chairmen: Marco Zucconi and Raffaele Ferri

09:00 - 09:10	Welcome and Introduction: Marco Zucconi
<u>Objective</u>	
09:10 - 09:30	PLMS as a tool for the diagnosis of RLS and the evaluation of drug effects Mauro Manconi, Switzerland
09:30 - 09:50	Do PLMW and SIT improve the specificity of PLMS for the diagnosis and treatment effect evaluation in RLS? Diego Garcia Borreguero, Spain and Marco Zucconi, Italy
09:50 - 10:10	Do sleep macro- and microstructure add something to the diagnosis and treatment effect evaluation in RLS? Raffaele Ferri, Italy
10:10 – 10:30	Is there a role for the pharmacologic tests? Karin Stiasny-Kolster, Germany
10:30 – 10:50	Role and limits of actigraphy? Richard Allen, USA and Birgit Högl, Austria
10:50 – 11:10	Which is the role of peripheral nerve investigation for RLS diagnosis? Cornelius Bachmann, Germany
11:10 – 11:30	Coffee Break -
<u>Subjective</u>	
11:30 – 11:50	RLS Diagnostic Index vs. IRLSSG criteria and other questionnaires for the diagnosis of RLS Heike Benes, Germany
11:50 – 12:10	IRLS, RLS-6 and other severity scales to measure the effect of treatment for RLS Ralf Kohnen, Germany
12:10 – 12:30	Quality of life (QoL) and depression/anxiety symptom measures for the assessment of treatment in RLS Jan Wesström, Sweden
12:30 – 12:50	Other subjective items/scales to test RLS complications or side effects (augmentation, impulsive control disorders, etc) Rosalia Silvestri, Italy
12:30 – 12:50 12:50 – 13:15	(augmentation, impulsive control disorders, etc)

EURLSSG-Meeting and Workshop are sponsored by:

F. Hoffmann-La Roche Ltd., Pfizer Inc., UCB Pharma S.A., Vifor Pharma Deutschland GmbH, XenoPort Inc.